ÂÜÀòÂÒÂ×

Xiying Qu is a seasoned scientist with extensive experience in pharmacology, molecular biology, and cancer therapy. Currently serving as Principal Scientist at Ampersand Biomedicines since October 2021, Xiying leads the in vivo team to assess the efficacy of antibody candidates and explore their mechanisms of action. Previous positions include Senior Scientist at E25Bio, where innovative technologies for detecting viral diseases were developed, and Instructor at Massachusetts General Hospital, focusing on mGluRs as cancer therapy targets. Earlier research involved evaluating HIV dynamics in postdoctoral roles at the University of Pittsburgh and Fudan University, as well as contributions to cancer therapy targets during a PhD and lecturer roles. Xiying holds a Ph.D. in clinical diagnosis of Laboratory Science from Wuhan University, a Master's in Biochemistry and Molecular Biology from Guangdong Medical University, and a Bachelor's in Biotechnology from Ludong University.